iiinova — where your digital self keeps evolving

ProQR Therapeutics @proqr.bsky.social · 08/10/2026

This #LiverAwarenessMonth, we’re raising awareness of #BiliaryAtresia (BA), a rare liver disease that affects newborns and young children. For more information about BA, visit our website: bit.ly/3VykIN6 #RareDisease #PediatricLiverDisease #Axiomer #RNAEditing #LiverHealth

000

ProQR Therapeutics @proqr.bsky.social · 25/09/2026

On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”. For additional information about the event and to register, visit: www.proqr.com/events #Axiomer #RNAEditing

cover slide with text “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” dated September 30, 2026

000

ProQR Therapeutics @proqr.bsky.social · 25/09/2026

Axiomer Insights: Our team published findings in Scientific Reports on preclinical liver models for ADAR-mediated RNA editing. Monica from our research team discusses how model selection can inform translatability for our #Axiomer #RNAEditing platform. Read the paper here: bit.ly/3UWJLZz

000

ProQR Therapeutics @proqr.bsky.social · 23/09/2026

ProQR welcomes Chris Hart as Chief Data & AI Officer and Thomas Wolf as Strategic AI Advisor to the Board. Their appointments support our strategy to apply AI across discovery and development. AX-0811, the first AI-discovered ProQR program is now in clinical trials. #Axiomer #RNAEditing

100

ProQR Therapeutics @proqr.bsky.social · 31/08/2026

Meet Anne Geert from our CMC team! He is responsible for producing the drug substances used in our preclinical and clinical programs. He also helps organize the ProQR conference. Learn more: bit.ly/4gjPtgA #Axiomer #TeamProQR

000

ProQR Therapeutics @proqr.bsky.social · 13/08/2026

Today we released our Q2 2026 financial results and provided a business update. Read the full press release on our website: bit.ly/45pX5Ic $PRQR #Biotech #Axiomer #RNAEditing

010

ProQR Therapeutics @proqr.bsky.social · 06/07/2026

The fifth Axiomer Summit brought ProQRians together for a day of science, collaboration, and cutting-edge discussions on our #Axiomer #RNAEditing platform. Thank you to our Scientific Advisory Board and Board members for their contributions. #Biotech #Innovation

010

ProQR Therapeutics @proqr.bsky.social · 25/06/2026

ProQR has made available a video featuring it’s Management Team discussing the Phase 1 AX-0810 data, the clinical validation of the #Axiomer #RNAEditing platform, AX-0811 and next steps with NTCP. Watch here: bit.ly/3QZpq4o

000

ProQR Therapeutics @proqr.bsky.social · 27/05/2026

Last week, ProQR co-founder Dinko Valerio joined the team to reflect on ProQR’s journey from an ambitious idea to advancing our #Axiomer #RNAEditing platform in the clinic. We are grateful to Dinko for his contributions over the years and for sharing his passion and insights with us.

000

ProQR Therapeutics @proqr.bsky.social · 15/05/2026

Today is #MPSAwarenessDay. #Hurlersyndrome is a severe form of MPS and is associated with significant disease burden, impacting quality of life and life expectancy. We recently announced AX-0422, a potential #RNAEditing therapy in development for Hurler syndrome. #ShineforMPS

000

ProQR Therapeutics @proqr.bsky.social · 12/05/2026

We’re excited to share that ProQR will present new data across multiple scientific conferences this May, highlighting the breadth of our Axiomer™ RNA editing platform. For more details, check out the PR: bit.ly/42qfJy9 #RNAEditing #Biotech

000

ProQR Therapeutics @proqr.bsky.social · 08/04/2026

Today we highlighted key updates in our Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810.” Check out the PR for more details bit.ly/4tEAbXC and watch the replay of the event: bit.ly/3PZBL7N #Axiomer #RNAEditing

010

ProQR Therapeutics @proqr.bsky.social · 08/04/2026

In one hour, at 10:00 ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”. For additional information about the event and to register, visit: lifescievents.com/event/g09guf... #Axiomer #RNAEditing

000

ProQR Therapeutics @proqr.bsky.social · 08/04/2026

We’re excited to introduce our partnership with Ginkgo Bioworks and in addition our AI Advisory Board, helping to bring #Axiomer #RNAEditing therapies to patients faster. Learn more at our Virtual Investor & Analyst event today at 10:00 ET: lifescievents.com/event/g09guf...

000

ProQR Therapeutics @proqr.bsky.social · 25/03/2026

On April 8th at 10:00 am ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”. For additional information about the event and to register, visit: lifescievents.com/event/g09guf... #Axiomer #RNAEditing

000

ProQR Therapeutics @proqr.bsky.social · 12/03/2026

Today we released our 2025 year end financial results and provided a business update. Read the full press release on our website: www.proqr.com/press-releas... $PRQR #Biotech #Axiomer #RNAediting

000

ProQR Therapeutics @proqr.bsky.social · 03/03/2026

Driven by a deep curiosity about molecular biology, Seda translates emerging science into strategic direction in her role as Senior Director, Research Strategy and Innovation at ProQR. Explore Seda’s profile and meet other members of #TeamProQR on our website: bit.ly/4b3BCXZ #RNAEditing #Axiomer

010

ProQR Therapeutics @proqr.bsky.social · 27/02/2026

At #TIDESAsia in Tokyo, our Chief Scientific Officer, Gerard Platenburg, shared how we are translating #Axiomer #RNAEditing into liver and CNS applications. You can explore the presentation here: www.proqr.com/presentation...

000

ProQR Therapeutics @proqr.bsky.social · 11/02/2026

Today we recognize the 11th anniversary of International Day of Women and Girls in Science! We caught up with Cristina Lopez Lopez, MD, PhD, CMO at ProQR, who shared her message for aspiring #WomenInScience. #IDWGS2026 #Feb11 #EveryVoiceInScience

020

ProQR Therapeutics @proqr.bsky.social · 09/02/2026

Today, ProQR announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next AGM as their terms conclude. We would like to sincerely thank Dinko and Alison for their valuable contributions to ProQR during their tenures.

100

ProQR Therapeutics @proqr.bsky.social · 29/01/2026

Carles is a Researcher at ProQR, combining a passion for biology with hands-on #RNAEditing research. Beyond the lab, he actively supports an inclusive and welcoming culture as part of the DEI team! Meet more members of the ProQR team: bit.ly/3M09Gvm #Axiomer #TeamProQR

000

ProQR Therapeutics @proqr.bsky.social · 08/01/2026

Proud to share our latest update highlighting encouraging initial safety and PK data with AX-0810 (cholestatic diseases), Development Candidate selection for AX-2402 (Rett syndrome) and AX-2911 (MASH), and strong momentum heading into 2026 as we advance our #Axiomer platform at ProQR.

100

ProQR Therapeutics @proqr.bsky.social · 22/12/2025

Our recent edition of the Axiomer Summit brought insightful discussions, a dynamic poster session, and exciting platform updates. Thanks to our SAB and Board for their valuable contributions! #RNAEditing #Axiomer #Biotech

020

ProQR Therapeutics @proqr.bsky.social · 21/11/2025

Great to connect with the community at #TIDESEU in Basel last week. Gerard Platenburg, our Chief Scientific Officer, presented on translating #Axiomer RNA Editing science into targeted CNS applications. Check out the presentation here: bit.ly/3K2y927 #RNAEditing

020

ProQR Therapeutics @proqr.bsky.social · 03/11/2025

The replay of our Investor and Analyst Event is now available: bit.ly/43PqFWS Thanks to Professor Verkade for joining us! We are delighted that AX-0810 progressing to the clinic. #Axiomer #RNAEditing $PRQR

000

ProQR Therapeutics @proqr.bsky.social · 03/11/2025

Join us in 60 mins for our virtual Investor and Analyst Event with ProQR Management and KOL Prof. Henkjan Verkade, MD, PhD (UMC Groningen). Register for the event here: bit.ly/3Lb7GzE #Axiomer #RNAEditing $PRQR

000

ProQR Therapeutics @proqr.bsky.social · 27/10/2025

Join us Nov 3 at 10:00 ET for our virtual Investor and Analyst Event with the ProQR Management and KOL Prof. Henkjan Verkade, MD, PhD (UMC Groningen). Register for the event here: bit.ly/3Lb7GzE #Axiomer #RNAEditing

000

ProQR Therapeutics @proqr.bsky.social · 22/10/2025

October marks #RettSyndromeAwarenessMonth, a time to shine a light on Rett syndrome. At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.

010

ProQR Therapeutics @proqr.bsky.social · 20/10/2025

We’re excited to share that our CTA for the Phase 1 study of AX-0810 in healthy volunteers has been authorized! Join our virtual Investor and Analyst Event Nov 3, 10:00 ET. For more details, check out the PR: bit.ly/3LjRCLX #Axiomer #RNAEditing

000

ProQR Therapeutics @proqr.bsky.social · 15/10/2025

David, Senior Scientist at ProQR, plays a key role in advancing cell biology research while also contributing to team leadership and workplace culture. Meet the rest of our team at: bit.ly/4nbVZWR #Axiomer #RNAEditing #TeamProQR

010

ProQR Therapeutics @proqr.bsky.social · 26/08/2025

Lemelinda pairs her passion for RNA biology with research, protocol development & biosafety support, while also fostering a strong community at ProQR through our Coffee & Collaboration Café. Meet more of the ProQR team at: bit.ly/45ZFtmq #Axiomer #RNAEditing #TeamProQR

000

ProQR Therapeutics @proqr.bsky.social · 07/08/2025

Today we announced our Second Quarter 2025 Operating and Financial Results. Read the press release here: bit.ly/4fwEU7Y $PRQR #RNAEditing #Axiomer

graphic with text "Financial Filings" and sub text that reads "2025 Q2 Report"

000

ProQR Therapeutics @proqr.bsky.social · 25/07/2025

Great to connect with the local community at the Dutch Medicines Summer Afternoon! Our VP Axiomer Science, Lenka van Sint Fiet, demonstrated how #Axiomer is driving progress toward potentially transformative therapies. #RNAEditing #DutchBioScienceWeek

000

ProQR Therapeutics @proqr.bsky.social · 22/07/2025

As R&D Team Manager at ProQR, Lorenza drives scientific collaboration and project planning while also championing inclusivity as part of our DEI team. Meet the ProQR team at: bit.ly/4m4oZzs #Axiomer #RNAEditing #TeamProQR

000

ProQR Therapeutics @proqr.bsky.social · 26/06/2025

We are happy to announce the submission of a CTA to the EMA to initiate a Phase 1 clinical trial in healthy volunteers for AX-0810 targeting NTCP. Check out the press release for more details: bit.ly/4ljFzuQ #Axiomer #RNAEditing #BiotechNews

000

ProQR Therapeutics @proqr.bsky.social · 12/06/2025

At ProQR, we’re proud to foster a culture where everyone feels safe to be themselves. To celebrate #Pride, our DEI team hosted a rainbow themed coffee & collaboration event with multicoloured cakes and a movie night featuring an LGBTQIA+ film and discussion. #Inclusivity #RNAEditing #Axiomer

010

ProQR Therapeutics @proqr.bsky.social · 06/06/2025

This week we held our biannual Axiomer Summit event – a day of vibrant discussions, insightful presentations, and an engaging poster session focused on our science. Thanks to our Scientific Advisory Board and Board members for joining this exciting exchange! #RNAEditing #Axiomer #Biotech

000

ProQR Therapeutics @proqr.bsky.social · 05/06/2025

From Amsterdam to New Orleans to San Diego – the month of May brought many connections with the field at #EASL, #ASGCT2025, and #TIDESUSA. Posters and presentations from ASGCT and TIDES are available on our website under Presentations and Publications. bit.ly/4kPCen7

000

ProQR Therapeutics @proqr.bsky.social · 08/05/2025

Today we announced our First Quarter Operating and Financial Results. Read the press release here: bit.ly/4dhMSRe $PRQR #RNAEditing #Axiomer

000

ProQR Therapeutics @proqr.bsky.social · 25/04/2025

ProQR is officially a Great Place to Work! We’re proud to foster a culture where innovation, collaboration, and growth thrive—driven by our amazing team and our mission to develop transformative RNA therapies. bit.ly/42LdvZR #GPTW #Biotech #RNAEditing #Axiomer

010